Marshall Wace’s Design Therapeutics DSGN Stock Holding History

Marshall Wace’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-151,008	Closed	-$1.61M	–	3293
2026 Q1	$1.61M	Sell	151,008 -74,520	-33%	-$754K	﹤0.01%	1908
2025 Q4	$2.12M	Buy	+225,528	New	+$1.77M	﹤0.01%	1550
2024 Q4	–	Sell	-17,192	Closed	-$92.5K	–	2673
2024 Q3	$92.5K	Sell	17,192 -7,088	-29%	-$33.3K	﹤0.01%	2382
2024 Q2	$81.3K	Buy	+24,280	New	+$94.6K	﹤0.01%	2406
2023 Q4	–	Sell	-60,542	Closed	-$143K	–	2262
2023 Q3	$143K	Sell	60,542 -52,380	-46%	-$244K	﹤0.01%	2013
2023 Q2	$711K	Sell	112,922 -67,997	-38%	-$416K	﹤0.01%	1856
2023 Q1	$1.04M	Buy	180,919 +68,101	+60%	+$509K	﹤0.01%	1791
2022 Q4	$1.16M	Buy	+112,818	New	+$1.53M	﹤0.01%	2023

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace's DSGN Position: Q2 2026 in Review

Marshall Wace sold out of Design Therapeutics (DSGN) in Q2 2026, closing a stake of 151,008 shares — an estimated $1.61M sold.

Marshall Wace first reported a position in DSGN in Q4 2022 and held it in 8 quarters. The position peaked at $2.12M in Q4 2025. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Marshall Wace reported no remaining Design Therapeutics position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 151,008 Design Therapeutics shares in Q2 2026, an estimated $1.61M.
Marshall Wace first reported a position in Design Therapeutics in Q4 2022 and held it in 8 quarters.
Marshall Wace's Design Therapeutics position peaked at $2.12M in Q4 2025.
137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.